U.S. Stock Futures Modestly Higher, Nasdaq Futures Lead Rebound
Markets are attempting to recover this morning after Wednesday's geopolitical-driven selloff, with U.S. stock futures moving modestly higher as oil prices retreat from recent highs. Nasdaq futures are leading the rebound, supported by renewed buying in semiconductor stocks, while investors assess the latest developments in the U.S.-Iran conflict and their potential impact on inflation and global growth.Although the U.S. launched another round of strikes against Iran and Tehran retaliated by targeting U.S. military facilities in Bahrain and Kuwait, investors appear encouraged by signs that neither side is seeking a prolonged disruption to energy markets. Oil prices have pulled back after an early spike, helping improve sentiment across equities and easing some concerns about another inflation shock.The Federal Reserve remains an important backdrop after minutes from the June meeting showed policymakers divided over the path of interest rates. While the Fed left rates unchanged, several officials expressed concern that higher energy prices and continued AI-related investment could keep inflation elevated, reinforcing expectations that another rate increase later this year remains possible. Investors will also watch the weekly jobless claims report and comments from New York Fed President John Williams for additional clues on the economic outlook.In pre-market trading, S&P 500 futures rose 0.23%, Nasdaq futures rose 0.91% and Dow futures rose 0.05%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Amco-Pittsburghup 11% after announcing that customer order activity during the first six months of 2026 totaled approximately $268M, an increase of 32% compared to the same period in 2025UP AFTER EARNINGS -Simply Good Foodsup 16%AZZ Inc.up 8%Triple Flagup 1%DOWN AFTER EARNINGS -Byrna Technologiesdown 19%Levi Straussdown 3%PepsiCodown 2%LOWER -Ionis Pharmaceuticalsand AstraZenecadown 20% and 8%, respectively, after Ionis and partner AstraZeneca announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpointSalesforcedown 1% after KeyBanc downgraded the stock to Sector Weight from OverweightStellantisdown 1% after JPMorgan downgraded shares to Neutral